Drugs / S-Tenatoprazole
S-Tenatoprazole
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00284908 | Sep → Nov 2006 | duodenal ulcer, esophagitis, gastric ulcer, gastroesophageal reflux disease | STEBA France | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00282555 | Feb 2006 → ? | gastroesophageal reflux disease | STEBA France | Suspended | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S-Tenatoprazole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00284908 ↗ |
| Known as | S-Tenatoprazole-Na | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00282555 ↗ |
| Known as | STU-Na | “S-Tenatoprazole-Na (STU-Na)” NCT00282555 ↗ |
| Route | Oral | “one of the dosages will be orally administered for five days.” NCT00284908 ↗ |